Serum miR-145-5p as a predictive biomarker for postoperative pain after percutaneous kyphoplasty

Thoracolumbar compression fractures are common in older adults. Percutaneous kyphoplasty (PKP) is a standard minimally invasive treatment, but 30%-50% of patients still have persistent or inadequate pain relief after the procedure.

To investigate the predictive value and mechanism of serum microRNA-145-5p (miR-145-5p) in PKP-related postoperative pain and to support precise pain assessment and intervention.

Ninety-five patients with thoracolumbar compression fractures treated with PKP were divided into a low pain group (49 cases, VAS 0-3) and a high pain group (46 cases, VAS 4-10) based on 1-month postoperative VAS scores. Fasting venous blood was collected preoperatively and 1 month postoperatively. Serum miR-145-5p and erythroblastic oncogene B4 (ErbB4) levels were measured by qPCR. An LPS-induced inflammatory model was established in RSC96 cells, and their target relationship and effects on inflammation were assessed via cell transfection, enzyme-linked immunosorbent assay (ELISA), and a dual-luciferase reporter gene assay. Logistic regression identified influencing factors, and ROC analysis evaluated the predictive value of miR-145-5p.

The high pain group had higher preoperative VAS scores, lower bone density T-scores, lower miR-145-5p levels and higher ErbB4 levels. miR-145-5p targets the 3'UTR of ErbB4, inhibiting inflammation by regulating ErbB4. Preoperative VAS score, bone density T-score, and miR-145-5p level were independent predictors of moderate-to-severe postoperative pain. Preoperative miR-145-5p had predictive value.

Preoperative serum miR-145-5p is a potential biomarker for assessing PKP-related postoperative pain, aiding precise intervention.